IDH1 and central nervous system cancer: The lowest recurrence rate (3/8) of IDH1 (R132H) U87 tumor was achieved and the survival rate of mice reached to 82.5% within 60 days, providing a good paradigm for the post‐surgical treatment of IDH1 (R132H) glioma.